Importance:
Sacral neuromodulation (SNM) requires removal for infectious complications in 3-11%.
Objective: Does preoperative antibiotic choice impact device removal rates?
Study Design:
This was a retrospective cohort analysis, using the Health Facts® Database, representing >750 hospitals. We included female patients undergoing SNM
implantation 2010-2018. Univariate and multivariate logistic regression identified factors associated with removal. 35 comorbidities were evaluated. Those with p<0.2 on univariate analysis were included in the multivariate analysis. We decided a priori to include prophylactic antibiotic choice in the final model.
Results:
Of 1,433 patients, 170 (11.9%) had device removal. Subjects were 70.0 ± 14.9 years old, predominantly Caucasian (90.0%), treated in urban hospitals (94.1%),
and married (54.2%). 11.8% were obese, and 18.0% smoked. Those in the removal cohort were more likely from the Northeastern U.S. 52.3% received 1st gen cephalosporins (CPSN), 7.4% 2nd or 3rd gen CPSNs, 9.1% vancomycin, 13.4% aminoglycosides, 4.6% clindamycin, and 13.3% fluoroquinolones. Compared to vancomycin, more removals were associated with first generation CPSNs (OR=3.1, 95% confidence interval [1.4, 6.8]); clindamycin (OR=3.2, [1.2, 8.4]); second/third generation CPSNs (OR=3.1, [1.3, 7.6]); and aminoglycosides (OR = 3.1, [1.3, 7.4]). Additionally, patients treated in the Northeast were more likely to undergo removal (OR = 1.9, [1.0, 3.7]).
Conclusions: Vancomycin as a prophylactic antibiotic was associated with fewer device removals compared to most antibiotics in this retrospective cohort analysis. While prospective trials could confirm this benefit, low removal rates may make this impractical.
Keywords: Sacral Neuromodulation, antibiotics, urinary incontinence, postoperative complications, device removal, infection